Fondaparinux as an alternative therapy in heparin-induced delayed-type hypersensitivity skin lesions [4]

Thrombosis and Haemostasis

Volumn 98, Issue 6, 2007, Pages 1389-1391

  O'Meara, Alix C ^a   Biasiutti, Franziska Demarmels ^b   Heizmann, Marc ^a  

^a Kantonsspital Aarau   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FONDAPARINUX; HEMOGLOBIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN;

AGED; BLOOD ANALYSIS; BRAIN INFARCTION; CASE REPORT; DELAYED HYPERSENSITIVITY; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEMATOCRIT; HEMIPARESIS; HOSPITAL ADMISSION; HUMAN; INJECTION SITE ERYTHEMA; LETTER; LEUKOCYTOSIS; MALE; MEDICAL LITERATURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SKIN DEFECT; THROMBOCYTE COUNT; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; DRUG ERUPTIONS; HUMANS; HYPERSENSITIVITY, DELAYED; INJECTIONS, SUBCUTANEOUS; MALE; NADROPARIN; POLYCYTHEMIA VERA; POLYSACCHARIDES; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 36949036472     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-05-0371     Document Type: Letter

References (22)

1. Bircher AJ, Harr T, Hohenstein L, et al. Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options. Allergy 2006; 61: 1432-1440.
2. Pierre R IM, Thiele J, Vardiman JW, et al. Polycythaemia vera. In: WHO Classification: Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press 2001; 32-34.
3. Utikal J, Peitsch WK, Booken D, et al. Hypersensitivity to the pentasaccharide fondaparinux in patients with delayed-type heparin allergy. Thromb Haemost 2005; 94: 895-896.
4. Handschin AE, Trentz O, Kock HJ, et al. Low molecular weight heparin-induced skin necrosis- a systematic review. Langenbecks Arch Surg 2005; 390: 249-254.
5. Gaigl Z, Pfeuffer P, Raith P, et al. Tolerance to intravenous heparin in patients with delayed-type hypersensitivity to heparins: a prospective study. Br J Haematol 2004; 128: 389-392.
6. Patel R, Lim Z, Dawe S, et al. Heparin-induced skin necrosis. Br J Haematol 2005; 129: 712.
7. Balestra B, Quadri P, Demarmels Biasiutti F, et al. Low molecular weight heparin-induced thrombocytopenia and skin necrosis distant from injection sites. Eur J Haematol 1994; 53: 61-63.
8. Warkentin TE, Roberts RS, Hirsh J, et al. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest 2005; 127: 1857-1861.
9. Fontana P, Bodmer A, Gruel Y, et al. Skin necrosis is a clinical manifestation of low-molecular weight heparin-induced thrombocytopenia. Thromb Haemost 2004; 91: 196-197.
10. Jappe U, Juschka U, Kuner N, et al. Fondaparinux: a suitable alternative in cases of delayed-type allergy to heparins and semisynthetic heparinoids? A study of 7 cases. Contact Dermatitis 2004; 51: 67-72.
11. Maetzke J, Hinrichs R, Schneider LA, et al. Unexpected delayed-type hypersensitivity skin reactions to the ultra-low-molecular-weight heparin fondaparinux. Allergy 2005; 60: 413-415.
12. Hohenstein E, Tsakiris D, Bircher AJ. Delayed-type hypersensitivity to the ultra-low-molecular-weight heparin fondaparinux. Contact Dermatitis 2004; 51: 149-151.
13. Hirsch K, Ludwig RJ, Lindhoff-Last E, et al. Intolerance of fondaparinux in a patient allergic to heparins. Contact Dermatitis 2004; 50: 383-384.
14. Mazzolai L, Hohlfeld P, Spertim F, et al. Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood 2006; 108: 1569-1570.
15. Koch P. Delayed-type hypersensitivity skin reactions due to heparins and heparinoids. Tolerance of recombinant hirudins and of the new synthetic anticoagulant fondaparinux. Contact Dermatitis 2004; 49: 276-280.
16. Parody R, Oliver A, Souto JC, et al. Fondaparinux (ARIXTRA) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins. Haematologica 2003; 88: 32.
17. Ludwig RJ, Schindewolf M, Utikal J, et al. Management of cutaneous type IV hypersensitivity reactions induced by heparin. Thromb, Haemost 2006; 96: 611-617.
18. Kher A, Bauersachs R, Nielsen JD. The management of thrombosis in pregnancy: role of low-molecular-weight heparin. Thromb Haemost 2007; 97: 505-513.
19. Sacher C, Hunzelmann N. Tolerance to the synthetic pentasaccharide fondaparinux in heparin sensitization. Allergy 2003; 58: 1318-1319.
20. Ludwig RJ, Beier C, Lindhoff-Last E, et al. Tolerance of fondaparinux in a patient allergic to heparins and other glycosaminoglycans. Contact Dermatitis 2003; 49: 158-159.
21. Maetzke J, Hinrichs R, Staib G, et al. Fondaparinux as a novel therapeutic alternative in a patient with heparin allergy. Allergy 2004; 59: 237-238.
22. Grims RH, Weger W, Reiter H, et al. Delayed-type hypersensitivity to low molecular weight heparins and heparinoids: cross-reactivity does not depend on molecular weight. Br J Dermatol 2007; 157: 514-517.